Legal Status Overview
Gray AreaNew Mexico has no peptide-specific law; the state's legal treatment of peptides such as BPC-157, TB-500, semaglutide/tirzepatide, and HGH is governed entirely by general federal drug and state pharmacy/compounding law rather than any New Mexico-specific peptide statute. The New Mexico Board of Pharmacy, part of the Regulation and Licensing Department, licenses pharmacies and pharmacists and administers the state's Pharmacy Act, Drug Device and Cosmetic Act, and Controlled Substance Act, but these do not carve out peptides or 'research chemicals' as a distinct category. As a result, FDA-approved peptide drugs remain prescription-only and dispensable through licensed New Mexico 503A/503B compounding pharmacies, while unapproved research-grade peptides circulate in an online market that state pharmacy regulators do not directly police.
Key Points
- The New Mexico Board of Pharmacy regulates pharmacies, pharmacists, and drug research facilities in New Mexico and administers the state's Pharmacy Act, Drug Device and Cosmetic Act, Controlled Substance Act, Drug Precursor Act, and Drug Product Selection Act, none of which single out peptides as a category. [1]
- No New Mexico-specific statute, administrative code section, or Board of Pharmacy rule naming 'peptides' or 'research chemicals' as a distinct legal category was found in New Mexico regulatory or legislative sources searched for this record. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- New Mexico's Board of Pharmacy has adopted the updated USP <797> sterile compounding standard, effective November 1, 2023, which governs how licensed New Mexico pharmacies must prepare sterile injectable products, including compounded peptides. [1]
- The FDA's October 2023 Category 2 designation bars 17 peptides, a group commonly cited as including BPC-157, from all pharmacy compounding nationwide, a federal restriction that binds any New Mexico-licensed 503A or 503B pharmacy regardless of the absence of a state-specific peptide rule. [8]
- The FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list, a federal move that would end large-scale compounded GLP-1 production nationwide, including at outsourcing facilities serving New Mexico patients. [5]
- Peptides sold online as 'research use only, not for human consumption' fall outside the New Mexico Board of Pharmacy's licensed-pharmacy oversight, since that board regulates the practitioner/compounding channel rather than the unregulated research-chemical marketplace. [3]
- No New Mexico-specific rule on personal importation, travel, or possession quantity limits for peptides was found; general federal law treats unapproved drugs brought in for personal use as a gray area that is rarely enforced against individual travelers, but this reflects general inference rather than a New Mexico-specific source. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- New Mexico patients can legally obtain compounded semaglutide and tirzepatide through licensed 503A compounding pharmacies operating in the state (for example in Santa Fe, Albuquerque, and Rio Rancho), but only with an individual patient prescription from a licensed provider. [10]
Peptide-by-peptide status in New Mexico
| BPC-157 | BPC-157 is not FDA-approved and, under the FDA's October 2023 Category 2 designation, cannot lawfully be compounded by any pharmacy in New Mexico or elsewhere, so within the state it exists only as an unapproved 'research use only' chemical outside the licensed pharmacy system. [8] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | Brand-name semaglutide and tirzepatide (e.g., Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved prescription-only drugs obtainable in New Mexico through licensed prescribers, and compounded versions have been dispensed by New Mexico 503A pharmacies under individual prescriptions, though the FDA is moving to close off further bulk compounding of these agents nationwide. [10] |
| TB-500 | No New Mexico-specific or definitive federal source was found addressing TB-500 by name, so its status in New Mexico is inferred, like other unapproved peptides, to fall into the unregulated 'research use only' research-chemical market rather than any licensed prescription pathway. |
| HGH (somatropin) | No New Mexico-specific statute on human growth hormone was identified in this research; its status in New Mexico is presumed, based on general knowledge of federal law, to be prescription-only, but this claim is not backed by a source located during this search and should be treated as unsourced. |
Sources
Last researched: 2026-09-09
Frequently asked questions
Can I buy peptides in New Mexico without a prescription?
Unapproved 'research use only' peptides can be purchased online in New Mexico without a prescription because that market sits outside the New Mexico Board of Pharmacy's licensed-pharmacy oversight, but any FDA-approved peptide drug (such as semaglutide or tirzepatide) legally requires a valid prescription in New Mexico. [3]
Can I bring peptides with me when traveling into New Mexico?
No New Mexico-specific rule on personal importation or travel quantities for peptides was found, so this reflects general federal drug-import principles rather than a documented New Mexico source.
Can I get compounded semaglutide or tirzepatide through telehealth in New Mexico?
Yes, New Mexico residents can obtain compounded semaglutide and tirzepatide through telehealth providers who prescribe and route orders to licensed 503A compounding pharmacies, provided each patient has an individual valid prescription. [10]
Is BPC-157 legal to buy in New Mexico?
BPC-157 is not FDA-approved and cannot legally be compounded by any pharmacy in New Mexico under the FDA's 2023 Category 2 restriction, so it is only available in the state, as elsewhere, through unregulated research-chemical sellers rather than a licensed prescription pathway. [8]
What are the penalties for possessing unapproved peptides in New Mexico?
No New Mexico-specific enforcement action or penalty schedule targeting individual possession of research-chemical peptides was found; federal and state pharmacy enforcement in this space has focused on sellers and compounding pharmacies (for misbranding or quality violations) rather than individual buyers. [7]